[フランクフルト／ロンドン １３日 ロイター] –European health officials said yesterday that an improved version of the messenger RNA (mRNA) vaccine for two new coronavirus strains in a single inoculation would soon improve people’s protection.
Moderna and Biontech / Pfizer are working on a vaccine based on a combination of the original “Wuhan” virus and an Omicron variant.
This vaccine, called a bivalent vaccine, will be used in the fall vaccination campaign. “It will be a good vaccine. (Omicron variant derivative) BA.4 / BA.5,” said Pierre Delsau, director of the European Union’s Department of Health Emergency Preparation and Response, at a hearing in the European Parliament. It will be a better vaccine against. “